Literature DB >> 8912089

Protective effect of cyclosporine A (CyA) against the hepatic injury associated with ischemia and reperfusion.

M F Sakr1, A N Abdel-Aal.   

Abstract

The putative hepatoprotective effect of cyclosporine A (CyA) against the hepatic injury associated with ischemia and reperfusion was studied in rats after a two-thirds hepatectomy following a 60-minute period of ischemia of the unresected liver. Animals were divided into three distinct groups of 10 rats each Group 1 (controls) received 0.5 ml saline solution intravenously (i.v.) while group 2 animals were injected with CyA (5 mg/kg) i.v., 24 hours before the induction of hepatic ischemia. The hepatic ATP content and serum levels of ALT and LDH were determined in each animal. Rats in group 3 were subjected to two-thirds hepatectomy only without the induction of ischemia. All controls died within 72 hours (group 1). Pretreatment of CyA improved the 7-day survival to 60% (p < 0.01). All group 3 animals survived through seven days. The improved survival seen in CyA pretreated animals as compared to controls was reflected by a restoration of hepatic ATP content and reduction in the serum levels of ALT and LDH postoperatively. Based on these results, it may be concluded that CyA ameliorates the hepatic injury associated with ischemia and reperfusion and allows the liver to recover and regenerate. Subsequently, survival is enhanced.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912089

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  2 in total

1.  Distinct contributions of CD4+ T cell subsets in hepatic ischemia/reperfusion injury.

Authors:  Satoshi Kuboki; Nozomu Sakai; Johannes Tschöp; Michael J Edwards; Alex B Lentsch; Charles C Caldwell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-03-05       Impact factor: 4.052

2.  Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation.

Authors:  Courtney M Lappas; Yuan-Ji Day; Melissa A Marshall; Victor H Engelhard; Joel Linden
Journal:  J Exp Med       Date:  2006-11-06       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.